J.P. Morgan analyst Anupam Rama has maintained their bullish stance on TVTX stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Anupam Rama has given his Buy rating due to a combination of factors that highlight Travere Therapeutics’ promising outlook. The company recently reported a strong third quarter for its product Filspari, which is primarily driven by robust demand in the IgAN market. This demand is expected to continue as the company efficiently manages patient conversion and time to fill prescriptions.
Additionally, the upcoming FSGS PDUFA date is anticipated to be a positive catalyst for the stock, with expectations of a smooth approval process. If approved, this could enhance Travere’s strategic profile significantly. Moreover, despite some seasonal fluctuations, the company has seen a strong trend in patient start forms, indicating sustained interest and potential growth. These factors collectively justify the Buy rating as Travere is positioned for long-term potential.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $47.00 price target.